Trevi Therapeutics (TRVI) Misses Q1 EPS by 2c

Trevi Therapeutics (NASDAQ: TRVI) reported Q1 EPS of ($0.11), $0.02 worse than the analyst estimate of ($0.09).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• Braze stock tumbles 10% on weak third quarter EPS guidance
• BMO Capital Starts Lululemon (LULU) at Underperform